Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ephedra Supplement Safety To Be Revisited At Senate Subcommittee Hearing

This article was originally published in The Tan Sheet

Executive Summary

An "independent analysis" of 14,700 ephedra-related adverse event reports received by Metabolife International will be discussed by the Senate Governmental Affairs/Oversight of Government Management Subcommittee during a hearing slated for Oct. 8
Advertisement

Related Content

Metabolife Federal Probe Spurs Release Of Ephedrine Complaint Records
Ephedra “Imminent Hazard” Declaration Sought By Sen. Durbin
Ephedra “Imminent Hazard” Declaration Sought By Sen. Durbin
Herbal Regulatory Category Creation At FDA Suggested By Sen. Durbin

Topics

Advertisement
UsernamePublicRestriction

Register

PS094613

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel